Cambrex Corporation (CBM) Getting Somewhat Favorable News Coverage, Report Finds
Media coverage about Cambrex Corporation (NYSE:CBM) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cambrex Corporation earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 48.4687689646501 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
A number of analysts have commented on the company. Craig Hallum reissued a “buy” rating and issued a $60.00 target price (down previously from $70.00) on shares of Cambrex Corporation in a report on Tuesday, October 31st. ValuEngine lowered Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Finally, BidaskClub lowered Cambrex Corporation from a “hold” rating to a “sell” rating in a report on Thursday, August 24th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $62.33.
Cambrex Corporation (CBM) traded up $1.45 during mid-day trading on Wednesday, hitting $49.55. The stock had a trading volume of 332,100 shares, compared to its average volume of 336,003. The stock has a market cap of $1,576.60, a P/E ratio of 15.17, a P/E/G ratio of 1.08 and a beta of 2.26. Cambrex Corporation has a 52-week low of $42.55 and a 52-week high of $62.95.
Cambrex Corporation (NYSE:CBM) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.47 by $0.08. The firm had revenue of $112.60 million for the quarter, compared to the consensus estimate of $108.44 million. Cambrex Corporation had a return on equity of 23.42% and a net margin of 18.79%. The company’s revenue for the quarter was up 13.4% on a year-over-year basis. During the same period last year, the business posted $0.47 EPS. research analysts forecast that Cambrex Corporation will post 2.97 earnings per share for the current year.
In related news, CEO Steven M. Klosk sold 4,000 shares of Cambrex Corporation stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $54.96, for a total transaction of $219,840.00. Following the transaction, the chief executive officer now directly owns 87,328 shares in the company, valued at $4,799,546.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Steven M. Klosk sold 12,000 shares of Cambrex Corporation stock in a transaction on Friday, September 1st. The shares were sold at an average price of $51.53, for a total value of $618,360.00. Following the transaction, the chief executive officer now owns 95,328 shares in the company, valued at $4,912,251.84. The disclosure for this sale can be found here. 2.48% of the stock is currently owned by insiders.
About Cambrex Corporation
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.